



2022 Development Grants for Funding Commencing in 2023

The [Development Grant scheme](#) provides financial support to individual researchers and/or research teams to undertake health and medical research within Australia at the proof-of-concept stage that specifically drives towards a commercial outcome within a foreseeable timeframe. The scheme supports the commercial development of a product, process, procedure or service that, if applied, would result in improved health care or disease prevention or provide health cost savings. Research supported by this scheme must, via a commercial business plan, have detailed feasible strategies for commercialisation that take into account the regulatory pathway, protectable Intellectual Property, commercial barriers and potential routes to market.

The 2022 Development Grants funding round seeking applications for funding commencing in 2023 opened on 20 April 2022. Applications closed on 15 June 2022 with 110 applications received.

The applications listed in table 1 have been approved for funding by the Minister for Health and Aged Care, the Hon Mark Butler MP.

Table 1. List of applications approved for funding

App ID	Chief Investigator Names	Application Title	Administering Institution	Budget
2022034	CIA - Prof Jonathan Baell CIB - Prof Ian Smyth CIC - Dr Yichao Zhao CID - Dr Denny Cottle CIE - Prof Andrew Mallett CIF - Dr David Shackleford	Development of bivalent degraders targeting Aurora kinase A for the treatment of polycystic kidney disease	Monash University	\$891,093.09
2022040	CIA - Prof Jonathan Baell CIB - Prof Rebecca Ritchie CIC - Dr Chengxue Helena Qin CID - Dr Lauren May CIE - Dr Elizabeth Vecchio CIF - Prof Gemma Figtree CIG - Dr David Shackleford CIH - Assoc Prof James Chong	Development of a new class of Formyl Peptide Receptor 1 (FPR1) biased agonists for the treatment of myocardial infarction	Monash University	\$944,924.64
2022050	CIA - Prof Christopher McDevitt CIB - Dr David Stamler CIC - Prof Mark Walker CID - Emer Prof Maree Smith CIE - Assoc Prof Tony Velkov	Breaking drug resistance in community-acquired bacterial pneumonia (CABP)	University of Melbourne	\$1,098,502.00

App ID	Chief Investigator Names	Application Title	Administering Institution	Budget
2022057	CIA - Prof Kim Delbaere CIB - Prof Peter Schofield CIC - Asst Prof Michael Bainbridge CID - Prof Nigel Lovell CIE - Prof Stephen Lord CIF - Prof Christopher Poulos CIG - Prof Anna Barker CIH - Ms Katherine Robinson CII - Dr Kimberley van Schooten	StandingTall: Digital fall prevention solution	University of New South Wales	\$1,296,922.80
2022075	CIA - Prof Leann Tilley CIB - Prof Craig Hutton CIC - Dr Stanley Cheng Xie	Mechanistically and chemically novel reaction-hijacking pro-inhibitors for malaria	University of Melbourne	\$514,089.00
2022121	CIA - Prof David Fairlie CIB - Prof Philip Hansbro	Developing a new type of drug for inflammatory lung disease	University of Queensland	\$981,805.00
2022218	CIA - Prof Lynne Bilston CIB - Prof Nigel Lovell CIC - Dr Peter Burke CID - Assoc Prof Leszek Lisowski CIE - Prof Peter Cistulli	Development of a novel optical stimulation therapy for obstructive sleep apnoea	University of New South Wales	\$1,137,447.00
2022337	CIA - Dr Jiawen Li CIB - Assoc Prof Peter Psaltis CIC - Prof Stephen Nicholls CID - Prof Robert Fitridge CIE - Prof Robert McLaughlin	Hybrid 3D-printed imaging catheter for more accurate cardiovascular disease detection	University of Adelaide	\$905,058.50
2022449	CIA - Assoc Prof Rebecca Lim CIB - Prof William Sievert CIC - Assoc Prof Joseph Rosenbluh CID - Dr Timothy O'Meara	Development of nanomedicine for non-alcoholic steatohepatitis	Monash University	\$890,458.00
2022583	CIA - Prof Colette McKay CIB - Prof Hugh McDermott CIC - Dr Darren Mao CID - Mr Robert Klupacs CIE - Dr Erol Harvey	EarGenie: A diagnostic system to transform the management of infants with hearing loss	Bionics Institute of Australia	\$1,176,999.50
2022585	CIA - Prof Jonathan Baell CIB - Prof Chris Langmead CIC - Dr Gregory Stewart CID - Assoc Prof Jess Nithianantharajah CIE - Dr Denise Wootten CIF - Dr David Shackelford	Development of novel GPR52 agonists for the treatment of schizophrenia	Monash University	\$779,955.00
2022625	CIA - Prof Daniel Christ CIB - Dr Greg Winter CIC - Emer Prof Mark Pepys	Development of a therapeutic monoclonal antibody	Garvan Institute of Medical Research	\$867,242.00

App ID	Chief Investigator Names	Application Title	Administering Institution	Budget
2022635	CIA - Prof Merlin Thomas CIB - Prof Stephen Wilton CIC - Dr Christopher Wraight CID - Dr Raelene Pickering	Splice switching oligonucleotides for the treatment of chronic kidney disease	Monash University	\$998,513.10
2022674	CIA - Prof Ivo Mueller CIB - Assoc Prof Jack Richards CIC - Mr William Hopper CID - Prof Leanne Robinson CIE - Dr Rhea Longley	Development of a Plasmodium vivax multi-analyte lateral flow assay to accelerate malaria elimination	Walter and Eliza Hall Institute of Medical Research	\$945,940.50
2022693	CIA - Assoc Prof Jason Lee CIB - Prof Trevor Perrior CIC - Assoc Prof Glen Boyle CID - Dr Arutha Kulasinghe CIE - Assoc Prof Victoria Atkinson	The development of DMX8.1 as a novel treatment for immunotherapy-refractory cancers	Council of the Queensland Institute of Medical Research	\$915,215.00
2022723	CIA - Prof Benjamin Thierry CIB - Prof Eva Bezak CIC - Assoc Prof Hien Le CID - Assoc Prof Lisa Ebert CIE - Assoc Prof Ivan Kempson CIF - Assoc Prof Ross Berbeco CIG - Dr David Waddington CIH - Dr Caterina Brighi CII - Prof Philip Low	Preclinical validation of a targeted theranostic agent for MRI guided radiotherapy and radiosensitisation of aggressive brain tumours	University of South Australia	\$837,678.00
			Total	\$15,181,843.13